The Fly | EQ

Today

Equillium initiated with bullish view at Piper Sandler, here's why

4:51 AM

Over a week ago

Equillium price target raised by $1 at Raymond James, here's why

May 28, 9:00 AM

Leerink upgrades Equillium on 'supportive' ulcerative colitis data

May 28, 6:25 AM

Leerink gets more bullish on Equillium, upgrades shares

May 28, 6:07 AM

Equillium appoints Snehal Naik as chief development officer

May 13, 4:06 PM

Equillium reports Q1 EPS (6c), consensus (4c)

May 13, 4:04 PM

Equillium initiated with bullish view at Oppenheimer, here's why

Apr 23, 6:32 AM

Equillium initiated with bullish view at B. Riley, here's why

Apr 16, 8:58 AM

Equillium initiated with bullish view at Raymond James, here's why

Apr 13, 4:09 PM

Equillium files to sell 18.88M shares of common stock for holders

Apr 7, 5:14 PM

Cantor starts Equillium at Overweight on ulcerative colitis potential

Apr 7, 7:27 AM

Equillium initiated with bullish view at Cantor Fitzgerald

Apr 7, 6:22 AM

Equillium reports Q4 EPS (4c), consensus (6c)

Mar 25, 4:15 PM

Equillium announces $35M financing with RA Capital Management

Mar 13, 8:21 AM

Equillium initiated with bullish view at Roth Capital, here's why

Mar 13, 5:30 AM

Equillium initiated with bullish view at Stifel, here's why

Feb 24, 4:31 PM

Equillium files $250M mixed securities shelf

Nov 13, 5:00 PM

Equillium terminates collaboration, license agreement with Biocon

Oct 6, 4:05 PM

Equillium files to sell 52.63M shares of common stock for holders

Sep 9, 5:01 PM

Equillium price target lowered by $4 at Jefferies, here's why

Aug 20, 3:51 PM

Equillium announces strategic expansion of cryptocurrency treasury strategy

Aug 4, 9:19 AM

No more stories

Novel CD6 Target and Mechanism of Action: Itolizumab targets the CD6 receptor, modulating T cell activation and differentiation through a unique pathway, offering a distinct therapeutic approach from commonly targeted pathways.

Broad Immunological Disease Applicability: The role of CD6 in T cell activation suggests therapeutic potential across multiple autoimmune and inflammatory diseases, allowing for pipeline diversification with a single asset.

Focus on High Unmet Medical Needs: Equillium is primarily developing itolizumab for severe, life-threatening conditions where existing treatments are inadequate, potentially allowing for premium pricing and rapid adoption if approved.

Clinical Trial Failure Risk: The lead product candidate, itolizumab, or other pipeline assets may fail to demonstrate efficacy or safety in ongoing or future clinical trials.

Regulatory Approval Uncertainty Risk: Even with positive clinical data, there is no guarantee that regulatory authorities will grant marketing approval for Equillium's drug candidates.

Competition and Market Share Risk: Equillium faces significant competition from larger pharmaceutical companies and other biotechs, which could limit market adoption or pricing power for its potential therapies.